Octimet is Biotechnology in Belgium that focus on biomarker-based strategies business. Founded in 2016. They cover business area such as developer, discovery stage molecule, cancer cell, cMET inhibitor, innovative patient selection, pharmacodynamic biomarker-base strategy, innovative clinical development, differentiation, competitor agent, biomarker-define intelligent patient selection, treatment, solid cancer.
2016
( 8 years old in 2024 )
Biomarker-based Strategies
-
Pieter Van Reysschootlaan 2/104
Sint-Denijs-Westrem
9051 Beerse
Belgium
Private
developerdiscovery stage moleculecancer cellcMET inhibitorinnovative patient selectionpharmacodynamic biomarker-base strategyinnovative clinical developmentdifferentiationcompetitor agentbiomarker-define intelligent patient selectiontreatmentsolid cancer
* We use standard office opening hours in near Octimet's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Octimet is Biotechnology business from Belgium that founded in 2016 (8 years old in 2024), Octimet business is focusing on Biomarker-based Strategies.
Octimet headquarter office and corporate office address is located in Pieter Van Reysschootlaan 2/104 Sint-Denijs-Westrem 9051 Beerse Belgium.
Octimet was founded in Belgium.
In 2024, Octimet is currently focus on biomarker-based strategies sector.
Above is snippet of Google Trends for "biomarker-based strategies" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Octimet, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
